Shanzhi Gu

LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial

S. Qin, L.S. Chan, Shanzhi Gu et al. · Annals of Oncology · 2022 · 99 citations

Medicine, Oncology, Pharmacology +12

Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial

Ying–Hong Shi, Guohong Han, Jian Zhou et al. · ˜The œLancet. Gastroenterology & hepatology · 2025 · 39 citations

Medicine, Oncology, Pharmacology +10

A Phase 1/2 Multicenter Randomized Trial of Local Ablation plus Toripalimab versus Toripalimab Alone for Previously Treated Unresectable Hepatocellular Carcinoma

Chunhui Zhou, Yan Li, Jiaping Li et al. · Clinical Cancer Research · 2023 · 22 citations

Medicine, Oncology, Pharmacotherapy +16

SCT-I10A combined with a bevacizumab biosimilar (SCT510) versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A randomized phase 3 trial.

Jianming Xu, Yanqiao Zhang, Gang Wang et al. · Journal of Clinical Oncology · 2024 · 16 citations

Pharmacy, Oncology, Pharmacotherapy +16